We have previously utilized a human bone morphogenetic protein-2 (BMP-2)-expressing recombinant adenoviral vector (AxCAOBMP-2) for osteoinductive gene therapy in rats. However, immunosuppression is essential for osteoinduction by AxCAOBMP-2 and this is one of the major impediments to its clinical use. Injection of AxCAOBMP-2 together with the immunosuppressant FK506 made it possible to markedly reduce the dose of the immunosuppressive agent and still induce ectopic bone reliably. We injected AxCAOBMP-2 and FK506 into the right calf muscle of rats, while the same number of plaque forming units of AxCAOBMP-2 and the same dose of FK506 placebo (vehicle) were injected into the left calf muscle. At 1, 3, 5, 7, 9 days after injection, BMP-2 mRNA expression was significantly higher in the right calf muscle than in the left calf muscle. At 21 days after injection, significantly more ectopic bone was observed in the right calf muscle than in the left calf muscle. These results indicate that coinjection of FK506 significantly promotes osteoinduction. In addition, local injection of FK506 may also make it possible to prevent a decrease of gene expression with other adenoviral vector.
Introduction
Bone morphogenetic proteins (BMPs) belong to the transforming growth factor -b superfamily and play an important role in osteogenesis and bone metabolism. 1, 2 Among them, BMP-2 has a very strong osteoinductive activity. Since recombinant human BMP-2 (rhBMP-2) has become available, many animal studies on the induction of bone formation by implantation of rhBMP-2 using various carriers have been performed. [3] [4] [5] However, it has been found that a large quantity of the recombinant protein is necessary for osteoinduction. Recently, some new osteoinductive gene therapies have been developed, such as in vivo electroporation with a BMP-containing plasmid expression vector. 6 However, osteoinduction by electroporation of a BMP-containing plasmid did not induce enough ectopic bone for clinical application, so a more effective method of gene therapy is needed.
We adopted an in vivo adenoviral vector system for transfer of the BMP-2 gene because of the ease of producing a high titer of recombinant virus and the high efficiency of gene transfer. 7, 8 However, adenoviral vectors have problems such as a short duration of activity and the occurrence of an immune response against transduced cells. In particular, the immune response against transduced cells has been identified as a major limitation of adenoviral vectors in animal studies of gene therapy. In previous studies, ectopic bone formation after injection of an adenoviral vector expressing BMP-2 was detected at intramuscular sites in immunodeficient animals, but not in immunocompetent animals. 9, 10 In order to induce ectopic bone by an adenoviral vector expressing BMP-2 in immunocompetent animals, temporary systemic immunosuppression has been employed in the past. 10, 11 On the other hand, some researchers have demonstrated that in vivo and ex vivo gene therapy using a BMP-2-expressing adenoviral vector without immunosuppression can repair segmental bone defects in immunocompetent animals. 12 , 13 Baltzer et al reported that in vivo gene therapy with a BMP-2-expressing adenoviral vector could repair segmental bone defects in immunocompetent animals. 12 They evaluated a site between the cut ends of bone, where local environment may have enhanced osteoinductive activity of the BMP-2-expressing adenoviral vector. To repair massive bone defects due to tumor surgery or traffic accidents, however, we consider that higher osteoinductive activity is essential, and gene therapy that can itself induce ectopic bone formation is required for rapid and adequate reconstruction. Lieberman et al 13 have demonstrated that the use of ex vivo adenoviral gene transfer to create BMP-2-producing bone marrow cells can repair segmental defects in immunocompetent animals. However, an ex vivo strategy might be expected to generate an immune reaction to adenoviral proteins, and it is more cumbersome and complicate for clinical application than in vivo methods.
Cyclosporin A and FK506 are the most commonly used immunosuppressants in organ transplantation. These drugs act in a similar manner to prevent T-cell activation, 14 but FK506 is more potent than cyclosporin A in vivo. 15 At present, therefore, FK506 is more widely used than cyclosporin A in patients undergoing organ transplantation, so we employed it as the immunosuppresssant for inducing ectopic bone formation by an adenoviral vector that expressed BMP-2 (AxCAOBMP-2). However, in order to induce a sufficient amount of ectopic bone using AxCAOBMP-2, we found that it was necessary to give high doses of FK506. 16 This is also one of the problems with using adenoviral vectors. By injecting a mixture of AxCAOBMP-2 and FK506, we succeeded in achieving local immunosupression at the site of administration with a low dose of FK506 and found that sufficient bone formation was induced. In the present study, we evaluated osteoinduction in rats using AxCAOBMP-2 plus FK506.
Results

Immunohistochemical findings
To evaluate the difference of the immune response after injection of Wistar rats with AxCAOBMP-2 (2.3 Â 10 7 plaque forming units (PFU)) plus FK506 (1.6 mg/kg) (FK506 group) or AxCAOBMP-2 (2.3 Â 10 7 PFU) plus FK506 placebo (1.6 mg/kg) (FK506 placebo group), we performed immunostaining with an anti-CD8 monoclonal antibody (Figure 1 ). At 1 day after administration, fewer infiltrating CD8 þ lymphocytes were detected in the FK506 group than in the FK506 placebo group. At 3 and 7 days after administration, however, there were no differences of CD8 þ lymphocytes between the two groups.
Adenoviral transduction of the LacZ gene in Wistar rats
To evaluate viral dissemination and destructive immune responses, AxCALacZ (2.3 Â 10 7 PFU) plus FK506 (1.6 mg/kg) were injected into the right calf muscle of rats (FK506 group), while AxCALacZ (2.3 Â 10 7 PFU) plus FK506 placebo (1.6 mg/kg) was injected into the left calf muscle of the same rats (FK506 placebo group). Then the expression of b-galactosidase was compared ( Figure 2 ). In the FK506 group, the expression of b-galactosidase peaked at 1 day after injection, decreased markedly by 3 days after injection, and decreased gradually thereafter. In the FK506 placebo group, b-galactosidase expression showed a peak at 1 day after administration and then decreased gradually. At 1 day after administration, bgalactosidase expression was significantly higher in the FK506 group than in the FK506 placebo group (twofold difference, Po0.05). At 3, 7, 14, and 21 days, the expression of b-galactosidase remained significantly higher in the FK506 group than in the FK506 placebo group (1.5-fold difference, Po0.01, Po0.01, Po0.005, and Po0.01, respectively).
Expression of BMP-2 and alkaline phosphatase (ALP) mRNA
We examined the differences in the expression of BMP-2 and ALP mRNA during the early stage of osteoinduction after injection of AxCAOBMP-2 (2.3 Â 10 7 PFU) and FK506 (1.6 mg/kg) (FK506 group) or AxCAOBMP-2 (2.3 Â 10 7 PFU) and FK506 placebo (1.6 mg/kg) (FK506 placebo group) in Wistar rats (Figure 3a) .
In the FK506 group, expression of BMP-2 showed a peak at 1 day after administration, decreased markedly at 3 days, and remained at approximately the same level thereafter. In the FK506 placebo group, BMP-2 expression showed a peak at 1 day after administration and then declined gradually, so that it was very weak by 5 days. The expression of BMP-2 was significantly stronger at all times in the FK506 group than in the FK506 placebo group. Gene therapy with BMP-2 adenovirus and FK506 S Kaihara et al Expression of ALP mRNA was observed from 5 days after injection in the FK506 group, and it increased gradually thereafter. In contrast, ALP expression was always very weak in the FK506 placebo group.
We also used nude rats to examined differences in the expression of BMP-2 and ALP mRNA during the early stage of osteoinduction after injection of AxCAOBMP-2 (2.3 Â 10 7 PFU) plus FK506 (1.6 mg/kg) (FK506 group) or AxCAOBMP-2 (2.3 Â 10 7 PFU) plus FK506 placebo (1.6 mg/kg) (FK506 placebo group) (Figure 3b ).
In the FK506 group, BMP-2 expression was high until 5 days after administration, but decreased markedly from 7 days onwards. In contrast, BMP-2 expression was high until 9 days after administration in the FK506 placebo group.
Expression of ALP mRNA was observed from 5 days onwards in the FK506 group. In contrast, ALP expression was always very weak in the FK506 placebo group.
Radiographic findings
At 21 days after injection of AxCAOBMP-2 plus FK506 or AxCAOBMP-2 plus FK506 placebo, Wistar rats underwent soft X-ray examination. AxCAOBMP-2 (2.3 Â 10 7 PFU) and FK506 (1.6 mg/kg) were injected into the right calf muscle of rats (FK506 group), while AxCAOBMP-2 (2.3 Â 10 7 PFU) and FK506 placebo (1.6 mg/kg) were injected into the left calf muscle of the same rats (FK506 placebo group) ( Table 1 ). Soft X-ray films revealed opacities in both groups. Opacities were observed in all specimens resected from the FK506 group, and two out of five specimens from the FK506 placebo group. The area of opacity was larger in the FK506 group than in the FK506 placebo group (Figure 4a ). In nude rats, opacities were also investigated by obtaining soft X-ray films on day 21. AxCAOBMP-2 (2.3 Â 10 7 PFU) plus FK506 (1.6 mg/kg) were injected into the right calf muscle (FK506 group) and Ax-CAOBMP-2 (2.3 Â 10 7 PFU) plus FK506 placebo (1.6 mg/kg) were injected into the left calf muscle of the same rats (FK506 placebo group) ( Table 1) . Soft X-ray films revealed opacities in both groups and the area of opacification did not differ between the FK506 and FK506 placebo groups ( Figure 4a ).
Histological findings and histomorphometric analysis
At 21 days after injection of AxCAOBMP-2 plus FK506 or AxCAOBMP-2 plus FK506 placebo into Wistar rats, light microscopy disclosed new bone formation in both groups. However, the trabecular bone area was significantly larger in the FK506 group than in the FK506 placebo group (Po0.001) (Figures 4b, c, and f). In nude rats, light microscopy also revealed new bone formation in both groups on day 21, but the trabecular bone area did not differ between the FK506 and FK506 placebo groups (Figures 4d-f ).
Biochemical indices
The ALP activity and calcium (Ca) content on day 21 after injection into Wistar rats are shown in Figures 5a and b, respectively. In the FK506 group, ALP activity was Figure 3 Expression of BMP-2 and ALP mRNA after injection of AxCAOBMP-2 (2.3 Â 10 7 PFU) plus FK506 (1.6 mg/kg) or Ax-CAOBMP-2 (2.3 Â 10 7 PFU) plus FK506 placebo (1.6 mg/kg) into the same Wistar rat. At 1, 3, 5, 7, and 9 days after administration, the injected region was excised, and the total RNA was extracted and analyzed by Northern blot analysis. In total, 30 ml total RNA was loaded per lane and hybridization was done with cDNA for BMP-2, ALP, or b-actin (a). The expression of BMP-2 and ALP mRNA after injection of AxCAOBMP-2 (2.3 Â 10 7 PFU) plus FK506 (1.6 mg/kg) or AxCAOBMP-2 (2.3 Â 10 7 PFU) plus FK506 placebo (1.6 mg/kg) into the same nude rat. At 1, 3, 5, 7, and 9 days after administration, the injected region was excised, and the total RNA was extracted and analyzed by Northern blot analysis. In total, 30 ml of total RNA was loaded per lane and hybridization was done with cDNA for BMP-2, ALP, or b-actin (b). Gene therapy with BMP-2 adenovirus and FK506 S Kaihara et al significantly higher than in the FK506 placebo group. The Ca content was also significantly higher in the FK506 group than in the placebo group (Po0.0005 and Po0.005, respectively). The ALP activity and Ca content in nude rats on day 21 after injection are displayed in
Figures 5a and b, respectively. Both ALP activity and Ca content showed no significant differences between the FK506 group and the FK506 placebo group.
Discussion
Thus far, attempts at adenovirus gene transfer into skeletal muscle have only achieved limited success in immunocompetent animals, since an immune response to the infected cells often occurs and results in the loss of therapeutic gene expression. 17, 18 CD8 þ and CD4 þ T cells have been shown to play a primary role in this decrease of gene expression. 18, 19 To modulate or avoid Tcell responses, several methods have been tried, such as inhibiting the CD28/B7 pathway, 20 blocking NF-kB activation, 21 inhibiting tumor necrosis factor-a activity, 22 and administration of an anti-CD4 antibody, 23 cyclophosphamide, 24 or FK506. 25 However, none of these methods of immunosuppression is sufficiently simple, effective, and free from side effects.
FK506 binds to FK506-binding protein (FKBP) and the FK506/FKBP complex inhibits calcineurin, a Ca 2 þ /calmodulin-dependent phosphatase. 26 Inhibition of calcineuurin leads to interleukin-2 (IL-2) gene transcription in T cells and consequently has an immunosuppressive effect. 27 Figure 4 Soft X-ray images of calf muscles (a). At 21 days after injection of AxCAOBMP-2 (2.3 Â 10 7 PFU) plus FK506 (1.6 mg/kg) or Ax-CAOBMP-2 (2.3 Â 10 7 PFU) plus FK506 placebo (1.6 mg/kg) into Wistar rats and nude rats, the injected region and the surrounding tissue were excised for soft X-ray examination. (FK506 group, upper row; FK506 placebo group, lower row). Histological features of new bone formation. At 21 days after injection of AxCAOBMP-2 (2.3 Â 10 7 PFU) plus FK506 (1.6 mg/kg) or AxCAOBMP-2 (2.3 Â 10 7 PFU) plus FK506 placebo (1.6 mg/kg) into Wistar rats and nude rats, the injected region and the surrounding tissue were excised and stained with hematoxylin and eosin (M, host calf muscle; NB, newly induced bone; BM, bone marrow) (original magnification, Â 25) FK506 group in Wistar rats (b), FK506 placebo group in Wistar rats (c), FK506 group in nude rats (d), FK506 placebo group in nude rats (e), histomorphometric analysis of bone formation in Wistar rats and nude rats (f). The trabecular bone area at 21 days after injection of AxCAOBMP-2 (2.3 Â 10 7 PFU) plus FK506 (1.6 mg/kg) or AxCAOBMP-2 (2.3 Â 10 7 PFU) plus FK506 placebo (1.6 mg/kg) was measured on films using a computer system with Photoshop (Version 5.5J; Adobe, Mountain View, CA, USA) and NIH image software (version 1.61). Data are expressed as the mean7s.d. (n¼5). Significant difference from the control (*Po0.001). 7 PFU) plus FK506 placebo (1.6 mg/kg) into the same Wistar and nude rats. At 21 days after injection, the treated region was excised. ALP was measured by the 4-nitrophenylphosphate method 35 and Ca was measured by the orthocresol-phthalein complex method. 34 Data are expressed as the mean7s.d. (n¼5). Significant difference from the control (*Po0.005, **Po0.0005).
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In the present study, we demonstrated that 1 day of administration of FK506 plus AxCAOBMP-2, there was less infiltration of CD8 þ T cells at the injection site compared with administration of FK506 placebo plus AxCAOBMP-2. At 3 and 7 days after administration, however, there were no differences in the infiltration of CD8 þ T cells between injection of AxCAOBMP-2 with or without active FK506 (Figure 1) . We also examined the infiltration of CD4 þ T cells and found that these cells showed the same pattern as CD8 þ T cells (data not shown). These results suggest that injection of FK506 was able to initially control the local immune response, but the benefit of local administration was lost by 3 days after injection.
Cells infected with AxCALacZ express b-galactosidase, and this acts as a marker of the transducing activity of the adenoviral vector. Since b-galactosidase is not a therapeutic gene, the level of b-galactosidase expression can also be used to assess the immunogenicity of potentially therapeutic gene products delivered by adenoviral vector. 28 Thus, the difference of b-galactosidase expression after injection of AxCALacZ with active FK506 or FK506 placebo is an indicator of the difference in immunosuppressive activity. In Wistar rats, the level of b-galactosidase expression after injection of FK506 was always significantly higher than after administration of FK506 placebo. The expression of b-galactosidase peaked at 1 day after administration of FK506, decreased dramatically by 3 days, and then continued to decreased gradually. In contrast, expression of b-galactosidase peaked at 1 day after administration of FK506 placebo and then decreased gradually (Figure 2 ). This difference in the pattern of gene expression indicates that the immune response was efficiently suppressed at 1 day after injection of AxCALacZ plus FK506, while the immunosuppressive effect of FK506 ceased by 3 days after injection at both the site of AxCALacZ plus FK506 injection and the site of AxCALacZ plus FK506 placebo injection.
In Wistar rats, expression of BMP-2 mRNA was significantly higher in the FK506 group than in the FK506 placebo group during the early stage of osteoinduction. In the FK506 group, BMP-2 expression showed a peak at 1 day after administration and then decreased gradually, so that it was hardly observed by 5 days after injection (Figure 3a) . The decline of BMP-2 expression after injection of AxCAOBMP-2 plus FK506 placebo was similar to that of b-galactosidase after the injection of this mixture. In contrast, BMP-2 expression showed a peak at 1 day after injection in the FK506 group, decreased dramatically at 3 days, and subsequently remained around the same level (Figure 3a) . These results suggest that injection of FK506 was able to effectively prevent a decrease of BMP-2 gene expression in the early stage of osteoinduction.
ALP is recognized as a marker of osteoblastic activity. ALP mRNA expression was detected in the FK506 group from 5 days after administration and it increased markedly thereafter. In contrast, ALP mRNA expression was very low in the FK506 placebo group during the early stage of osteoinduction (Figure 3a) . Expression of ALP indicates the onset of osteoinduction, so these results also suggest that injection of FK506 was able to effectively control the local immune response and prevent a decrease of gene expression.
We evaluated the late stage of osteoinduction in Wistar rats at 21 days after injection of AxCAOBMP-2 plus FK506 or AxCAOBMP-2 plus FK506 placebo using radiographic, histological, and biochemical examinations. New bone formation was observed in all specimens from the FK506 group and two out of five from the FK506 placebo group on radiographic and histological examination. The area of radiographic opacity was larger in the FK506 group than in the FK506 placebo group (Figure 4a) . Similarly, histological and histomorphometric examination showed that the trabecular bone area was larger in the FK506 group than in the FK506 placebo group (Figure4b, c, and f) . In Wistar rats, both the ALP activity and Ca content were significantly higher in the FK506 group than in the FK506 placebo group ( Figure 5 ). These results suggest that injection of FK506 may promote osteoinduction and induction of new bone formation. In our previous study, we made the same comparisons using other doses (0.4, 0.8, and 3.2 mg/kg) of FK506 and FK506 placebo. Below a dose of 1.6 mg/kg, the trabecular bone area, ALP activity, and Ca content increased dose-dependently in the AxCAOBMP-2 plus FK506 groups. However, these parameters showed no significant differences between FK506 doses of 1.6 and 3.2 mg/kg (data not shown). Therefore, we concluded that the appropriate dose of FK506 for Wistar rats was 1.6 mg/kg. Some researchers have reported that FK506 promotes osteoblast activity and is a useful agent for induction of bone formation or for allogeneic bone grafting. 29, 30 To determine whether our results were depended on the immunosuppressant or osteogenic effect of FK506, we examined the expression of BMP-2 and ALP mRNA at 1, 3, 5, 7, and 9 days after injection into nude rats and we also performed radiographic, histologic, histomorphometric, and biological assessment of nude rats at 21 days after injection. In the FK506 group, BMP-2 expression remained high until 5 days after administration, but was decreased markedly from 7 days onwards. In contrast, expression of BMP-2 continued until 9 days after administration in the FK506 placebo group (Figure 3b) . Expression of ALP mRNA was observed from 5 days after injection in the FK506 group and persisted thereafter. In contrast, ALP expression was always very weak in the FK506 placebo group (Figure 3b) . Our previous study showed that BMP-2 plays an important role in osteoinduction, especially in the early stage as well as at a later stage of the process (the stage of bone matrix formation by osteoblasts), so BMP-2 expression may be absent or very weak. 31 We consider that the decrease of BMP-2 expression in the FK506 group from 7 days after injection indicated a shift to the later stage of osteoinduction. ALP expression was detected as an indicator of the onset of osteoinduction in the FK506 group. In contrast, BMP-2 expression persisted until day 9 in the FK506 placebo group, while ALP expression was still very weak at 9 days after the injection (Figure 3b ). These findings suggest that the early stage of osteoinduction was still ongoing at 9 days after injection in the FK506 placebo group. Accordingly, FK506 seems to promote osteoblastic activity and the progression of osteoinduction. However, the radiographic, histologic, histomorphometric, and biological data obtained in nude rats at 21 days after injection revealed that there were no significant Gene therapy with BMP-2 adenovirus and FK506 S Kaihara et al differences between the FK506 and FK506 placebo groups (Figures 4 and 5) . Thus, although FK506 promoted osteoblastic activity and the early stage of osteoinduction, there were no differences between FK506 treatment and placebo treatment after 3 weeks. Our previous study showed that short-term administration of FK506 could promote earlier osteoinduction by rhBMP-2, but bone resorption also occurred earlier than in the absence of FK506. We speculated that the ectopic bone formed within muscle tissue was absorbed earlier because of the relative lack of mechanical stress acting on the new bone, 32 and the same phenomenon may have occurred in the present study. However, those results suggested that our findings are not only dependent on the immunosuppressive activity of FK506 but also on osteoblast activation by this drug.
In previous studies, in order to induce ectopic bone in immunocompetent animals, with an adenoviral vector expressing BMP-2, systemic immunosuppression was necessary. 10, 11 However, gene transfer using adenoviral vectors generally involves local administration and transduces cells in contact with the vector. Therefore, we considered that suppressing local immune response at the site of administration may be more important and enough to prevent a decrease of gene expression. Topical application of FK506 has been mainly used to treat skin diseases, such as atopic eczema, psoriasis, and contact allergy. Many researchers have demonstrated that topical application of FK506 can efficiently suppress epidermal T-cell recruitment. 33, 34 Thus, FK506 was able to suppress local T-cell recruitment at the site of administration. Moreover, it seems that topical FK506 inhibited the direct activation of infiltrating T cells that came into contact with the adenoviral vector. Such effects of topical FK506 could have great advantages over systemic administration. Mixing an adenovirus solution and FK506 is a simple and reliable method of ensuring the delivery of the drug to the site of vector administration. Although a primary immune response may develop after the immunosuppressive effect by FK506 wears off, osteoinduction by AxCAOBMP-2 only requires transient immunosuppression. Moreover, FK506 can potently promote the activity of osteoblasts induced by Ax-CAOBMP-2. Therefore, we consider that FK506 is the most suitable immunosuppressant, and that mixing FK506 and AxCAOBMP-2 is the most efficient method for local delivery of AxCAOBMP-2 in vivo. Mixing an adenovirus solution and FK506 suspended in saline is an extremely simple method for clinical application and no obvious toxic effects of FK506 administration of FK506 were observed on histological examination (date not shown).
Some authors have demonstrated that temporary systemic immunosuppression with FK506 can permit readministration of an adenoviral vector, 25, 35 so it is possible that local injection of FK506 may also allow administration of multiple doses of the adenoviral vector.
In addition, injection of FK506 with other adenoviral vectors may make it possible to prevent a decrease of gene expression and allow multiple dosing. In conclusion, gene therapy with a mixture of adenovirus and FK506 seem to be worth investigating for clinical use.
Materials and methods
Construction of the BMP-2-expressing recombinant adenoviral vector
The details of vector construction were described previously. 36 A replication-deficient recombinant adenoviral vector carrying the BMP-2 gene (AxCAOBMP-2) was constructed by the cosmid cassette and adenoviral DNA terminal protein complex method (COS/TPC; Adenoviral expression vector kit, Takara Shuzo Co., Ltd, Shiga, Japan), as described previously. 37 This vector system, with deletion of the E1 and E3 regions, 38 contained the human BMP-2 gene under the control of a CAG promoter (chicken b-actin promoter and cytomegalovirus enhancer).
The control vector was AxCALacZ 38 (a gift from I Saito and Y Kanegae), which carried Escherichia coli (E. coli) lacZ cDNA in the same expression unit as AxCAOBMP-2. The viruses were titrated and stored at À801C in phosphate-buffered saline (PBS) containing 10% glycerol. The titer of AxCAOBMP-2 and AxCALacZ was determined by the method described previously; 39 it was 2.3 Â 10 9 and 2.3 Â 10 9 PFU/ml, respectively.
FK506
FK506 or FK506 placebo (Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan) was suspended in saline, mixed with the virus solution, and injected into the calf muscle of each rat.
Animals
In total, 47 Wistar rats (male; 9 weeks old and weighing 230-250 g) were obtained from SLC JAPAN Inc. (Tokyo, Japan) and were randomly divided into the following groups: (1) a radiographic, histological, and biochemical evaluation group (five rats); (2) a Northern blot analysis group (five rats); (3) a b-galactosidase analysis group (25 rats); and (4) an immunohistochemical analysis group (12 rats) ( Table 1) . For radiographic evaluation, histological examination, and biochemical analysis, the FK506 group was created by injecting 10 ml of AxCAOBMP-2 (2.3 Â 10 9 PFU/ml) and 20 ml of FK506 (1.6 mg/kg) into the right calf muscle of rats; while the FK506 placebo group was created by injection of 10 ml of AxCAOBMP-2 (2.3 Â 10 9 PFU/ml) and 20 ml of FK506 placebo (1.6 mg/ kg) into the left calf muscle of the same rats.
For Northern blot analysis and immunohistochemical analysis, 10 ml of AxCAOBMP-2 (2.3 Â 10 9 PFU/ml) and 20 ml of FK506 (1.6 mg/kg) were injected into the right calf muscle of rats, while 10 ml of AxCAOBMP-2 (2.3 Â 10 9 PFU/ml) and 20 ml of FK506 placebo (1.6 mg/ kg) were injected into the left calf muscle of the same rats. For b-galactosidase analysis, 10 ml of AxCALacZ (2.3 Â 10 9 PFU/ml) and 20 ml of FK506 (1.6 mg/kg) were injected into the right calf muscle of rats, while 10 ml of AxCALacZ (2.3 Â 10 9 PFU/ml) and 20 ml of FK506 placebo (1.6 mg/kg) were injected into the left calf muscle of the same rats.
In all, 10 nude rats (F 344/N Jcl-rnu; male; 9 weeks old and weighing 170-190 g) were obtained from CLEA JAPAN Inc. (Tokyo, Japan) and were randomized to the following groups: (1) a group for radiographic, histological, and biochemical evaluation group (five rats) and (2) a Northern blot analysis group (five rats). For
Gene therapy with BMP-2 adenovirus and FK506 S Kaihara et al radiographic evaluation, histological examination, and biochemical analysis, the FK506 group was created by injecting 10 ml of AxCAOBMP-2 (2.3 Â 10 9 PFU/ml) and 20 ml of FK506 (1.6 mg/kg) into the right calf muscle; while the FK506 placebo group was created by injection of 10 ml of AxCAOBMP-2 (2.3 Â 10 9 PFU/ml) and 20 ml of FK506 placebo (1.6 mg/kg) into the left calf muscle of the same rats. For Northern blot analysis, 10 ml of Ax-CAOBMP-2 (2.3 Â 10 9 PFU/ml) plus 20 ml of FK506 (1.6 mg/kg) were injected into the right calf muscle of rats, while 10 ml of AxCAOBMP-2 (2.3 Â 10 9 PFU/ml) plus 20 ml of FK506 placebo (1.6 mg/kg) were injected into the left calf muscle of the same rats.
The animals were allowed free access to rodent chow (Certified diet MF; Oriental Koubo Inc., Tokyo, Japan) preoperatively and postoperatively. All procedures and virus inoculation were approved by the Institute of Laboratory Animals, Graduate School of Medicine, Kyoto University.
Surgical procedure
Following disinfection of the target region, the virus with FK506 or FK506 placebo mixture was injected once into the calf muscle using a microsyringe.
Immunohistochemical analysis
To evaluate the in vivo immune response of Wistar rats to the adenoviral vector, we injected 10 ml of AxCAOBMP-2 (2.3 Â 10 9 PFU/ml) and 20 ml of FK506 (1.6 mg/kg) into the right calf muscle of each rat, while 10 ml of AxCAOBMP-2 (2.3 Â 10 9 PFU/ml) and 20 ml of FK506 placebo (1.6 mg/kg) were injected into the left calf muscle of the same rats. The animals were killed at 1, 3, and, 7 days after injection. Then, cryosections (5 mm) were prepared and immunostaining was done with anti-CD8 monoclonal antibody. In brief, cryosections of muscle were rinsed twice with PBS for 5 min at room temperature, and then blocked with 0.1% sodium azide in 0.1% H 2 O 2 for 10 min at room temperature. Next, the sections were blocked in 10% BSA with 0.1% sodium azide for 10 min and then incubated for 2 h at room temperature with mouse anti-rat CD8 monoclonal antibodies (PharMingen, San Diego, CA, USA). The sections were rinsed twice more with PBS for 5 min each, incubated with peroxidase-conjugated AffiniPure goat anti-mouse IgG (H þ L) (Jackson, West Grove, PA, USA) for 30 min, and then rinsed twice with PBS. Peroxidase activity was visualized with 3-amino-9-ethylcarbazole (AEC Substrate-chromogen System, Dako, Carpinteria, CA, USA).
RNA extraction and Northern blot analysis
We injected 10 ml of AxCAOBMP-2 (2.3 Â 10 9 PFU/ml) and 20 ml of FK506 (1.6 mg/kg) into the right calf muscle of each rat, while 10 ml of AxCAOBMP-2 (2.3 Â 10 9 PFU/ ml) and 20 ml of FK506 placebo (1.6 mg/kg) were injected into the left calf muscle of the same rats. At 1, 3, 5, 7, 9 days after injection, the rats were killed. Then the injected region was excised and the total RNA was extracted by the acid guanidinium phenol chloroform (AGPC) method. Total RNA (30 mg/lane) was subjected to electrophoresis and transferred to a Hybond-N þ membrane (Amersham Pharmacia Biotech, Buckinghamshire, England). The probe for BMP-2 was the full-length cDNA of human BMP-2. The probe for rat ALP was prepared by the reverse-transcription polymerase chain reaction (RT-PCR). The probe for b-actin was obtained from Wako Pure Chemicals (Osaka, Japan). Complementary DNA (cDNA) probes were prepared using the random priming method in the presence of [a-32P]deoxycytosine triphosphate (dCTP; 3000 Ci/mmol) obtained from Amersham Japan (Tokyo, Japan). Hybridization was carried out at 421C in hybridization buffer (50% deionized formamide, 10% dextran sulfate, 5 Â SSC, 5 Â Denhardt's solution, 0.5% sodium dodecyl sulfate (SDS)) and 250 mg/ml of denatured salmon sperm DNA (Sigma). After soaking in 2 Â SSC, the filters were washed twice for 20 min at 421C in washing buffer (0.2 Â SSCÀ0.1% SDS) and then were analyzed by a Bioimage analyzer (BAS 2000; Fuji Film, Tokyo, Japan). Messenger RNA (mRNA) expression levels were normalized for b-actin mRNA expression.
Viral transduction of the LacZ gene
To evaluate in vivo dissemination of virus, we injected 10 ml of AxCALacZ (2.3 Â 10 9 PFU/ml). plus 20 ml of FK506 (1.6 mg/kg) into the right calf muscle of each Wistar rat, while 10 ml of AxCALacZ (2.3 Â 10 9 PFU/ml) plus 20 ml of FK506 placebo (1.6 mg/kg) were injected into the left calf muscle of the same rats. At 1, 3, 7, 14, and 21 days after injection, the rats were killed. The injected region was excised and immediately frozen in liquid nitrogen. Then, 200 mg of tissue was homogenized in 1.5 ml of reporter lysis buffer (Promega, Madison, WI, USA) and incubated for 15 min at room temperature. Cell debris were pelleted by centrifugation, after which the supernatant was transferred into another microcentrifuge tube and frozen at -801C until assay.
The b-galactosidase activity per 300 mg of protein from each tissue was measured with a b-galactosidase enzyme assay kit (Promega).
Radiographic evaluation
At 21 days after vector injection, the rats were killed with an overdose of sodium pentobarbital. Then the injected region was excised together with the surrounding tissue and subjected to soft X-ray examination (SOFRON; SRO-M50, Sofron Inc., Tokyo, Japan). Each excised specimen was then cut into halves, with one half being used for histological examination and the other for biochemical analysis.
Histological and histomorphometric examination
The specimens were fixed in 10% neutral-buffed formalin (pH 7.4), demineralized in ethylenediamine tetraacetic acid, and embedded in paraffin. Then 4 mm thick sections were cut and stained with hematoxylin and eosin.
For histomorphometric analysis, the trabecular area was measured on photomicrographs obtained on day 21 using a computer system with Photoshop (Version 5.5J; Adobe, Mountain View, CA, USA) and NIH image software (version 1.61).
Biochemical analysis
Samples were weighed and then were homogenized in 0.25 M sucrose using a Polytron homogenizer (BioMixer; type ABM, Nissei Inc., Osaka, Japan). The sediment was demineralized in 0.5 N HC1, and the Ca content of the soluble fraction was determined by the Gene therapy with BMP-2 adenovirus and FK506 S Kaihara et al orthocresol-phthalein complex method. 40 The ALP activity and total protein in the resultant supernatant were determined by the 4-nitrophenylphosphate method. 41 The Ca content (mg/mg tissue) and the ALP activity (IU/mg protein) were used as indices of bone formation.
Statistical analysis
Results are presented as the mean7standard deviation (s.d.). Statistical analysis of differences in the ALP activities and Ca contents was performed by analysis of variance (ANOVA).
